Methods for plant transformation using spectinomycin selection
First Claim
Patent Images
1. A method for producing a transgenic plant containing at least two heterologous nucleic acid sequences, comprising:
- (a) providing an explant comprising a first heterologous nucleic acid sequence that confers resistance to an herbicide, an aminoglycoside, or hygromycin;
(b) inoculating the explant with Agrobacterium comprising a vector which comprises a second heterologous nucleic acid sequence comprising a selectable marker gene conferring spectinomycin resistance;
(c) co-cultivating the explant with the Agrobacterium to obtain an explant that exhibits spectinomycin resistance; and
(d) regenerating the explant that exhibits spectinomycin resistance into a transgenic plant containing at least the two heterologous nucleic acid sequences;
wherein the explant is treated with a cytokinin at least during steps (b) and (c).
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods and compositions for transforming soybean, corn, cotton, or canola explants using spectinomycin as a selective agent for transformation of the explants. The method may further comprise treatment of the explants with cytokinin during the transformation and regeneration process.
40 Citations
10 Claims
-
1. A method for producing a transgenic plant containing at least two heterologous nucleic acid sequences, comprising:
-
(a) providing an explant comprising a first heterologous nucleic acid sequence that confers resistance to an herbicide, an aminoglycoside, or hygromycin; (b) inoculating the explant with Agrobacterium comprising a vector which comprises a second heterologous nucleic acid sequence comprising a selectable marker gene conferring spectinomycin resistance; (c) co-cultivating the explant with the Agrobacterium to obtain an explant that exhibits spectinomycin resistance; and (d) regenerating the explant that exhibits spectinomycin resistance into a transgenic plant containing at least the two heterologous nucleic acid sequences; wherein the explant is treated with a cytokinin at least during steps (b) and (c). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification